(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Nexi expands alliance with PayPal - 25 Home EV Chargers for Proficient and Solid Charging
- 3Best Amusement Park in Europe: Where Do You Very much want to Visit?
- 4‘Downton Abbey: The Grand Finale’ hits streaming: How to watch, cast info and everything you need to know
- 5Unraveling the Specialty of Picking Your Ideal Travel Objective
- Saturn shines with the waxing moon at sunset on Nov. 29
- Melodic Combination d: A Survey of \Unrecorded Music Energy\ Show
- Terminal cancer diagnosis announced by JFK's granddaughter
- Must-See Attractions in France
- At least 171 measles cases confirmed in 9 states, CDC data shows
- Change Your Physical make-up: Compelling Activities for Muscle Building
- UN panel says Israel operating 'de facto policy of torture'
- Heartfelt Objections to Visit with Your Adored One
- The 10 Most Persuasive Forerunners in Innovation
